✦ LIBER ✦

A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients

✍ Scribed by Sauter, Craig S.; Barker, Juliet N.; Lechner, Lauren; Zheng, Junting; Devlin, Sean M.; Papadopoulos, Esperanza B.; Perales, Miguel-Angel; Jakubowski, Ann A.; Goldberg, Jenna D.; Koehne, Guenther; Ceberio, Izaskun; Giralt, Sergio; Zelenetz, Andrew D.; Moskowitz, Craig H.; Castro-Malaspina, Hugo

Book ID: 122144817
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 619 KB
Volume: 20
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2013.11.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of Rituximab in rheumat

A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation

✍ Moore, J; Ma, D; Will, R; Cannell, P; Handel, M; Milliken, S 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 202 KB

Early Results of a Phase II Study Adding

Early Results of a Phase II Study Adding Peri-Transplant Rituximab to Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients (PTS) with High-Risk Fludarabine-Refractory Chronic Lymphocytic Leukemia (Cll)

✍ M.L. Sorror; B. Storer; B.M. Sandmaier; T. Chauncey; B. Bruno; N.N.S. Andersen; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 93 KB

Phase I study of a neutralizing monoclon

Phase I study of a neutralizing monoclonal anti-CTLA4 antibody (MDX-010) in patients with relapse of malignancy after allogeneic hematopoietic stem cell transplantation

✍ A. Bashey; B. Medina; R.-K. Zhong; J.-H. Zhou; E. Carrier; J. Castro; P. Holman; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 59 KB

A Phase I/II Study Of Cyclophosphamide a

A Phase I/II Study Of Cyclophosphamide and Topotecan In Patients With High-Risk Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation: The St. Jude Long-Term Follow-Up

✍ K.A. Kasow; R.C. Barfield; N.L. Wright; C. Li; D.K. Srivastava; E.M. Horwitz; W. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Haploidentical Transplantation Using T C

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial

✍ Solomon, Scott R.; Sizemore, Connie A.; Sanacore, Melissa; Zhang, Xu; Brown, Sta 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 264 KB

Identification of an AUC of 7603 Umol∗Mi

Identification of an AUC of 7603 Umol∗Min/Hr Per Day X 4 Days as the Maximum Tolerated Dose (MTD) of IV Continuous Infusion (CI) Busulfan (BU) with Fixed Dose Fludarabine (FLU) in A Pharmacokinetically-Based Dose Phase I Study in Patients (PTS) with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

✍ W.A. Wood; C.M. Walko; K.V. Rao; J. Whitley; D.T. Moore; D.A. Gabriel; J.S. Sero 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 45 KB